VEGF signaling pathway inhibitors (VSPI) such as bevacizumab, sorafenib, and sunitinib are widely used in terminating tumors such as renal, hepatocellular, thyroid, and gastrointestinal stromal tumors, and are associated with cardiovascular comorbidities such as HTN, with a reported incidence of 20–90%40. The gene discussed is VEGFA; the disease is hypertensive disorder.